| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 6, 2006
From the Division of Cardiology (A.D.C., J.T., C.R.-B., K.I.), Department of Physiology (F.R., J.C.B.), University Jean Monnet in Saint-Etienne, Saint-Etienne, France; Division of Cardiology, Firminy Hospital, Firminy, France (L.A.); Bakken Research Center, Maastricht, Netherlands (M.M.); Division of Cardiology, Saint-Chamond Hospital, Saint-Chamond, France (L.D.); Division of Cardiology, Valence Hospital, Valence, France (E.F.); Department of Medicine for the Elderly, La Charité Hospital, Saint-Etienne, France (R.G.); Division of Cardiology, Feurs Hospital, Feurs, France (G.K.); Division of Cardiology, Montbrison Hospital, Montbrison, France (J.M.P.); Division of Cardiology, Annonay Hospital, Annonay, France (S.B., T.G.); Division of Cardiology, University of Clermont-Ferrand, Clermont-Ferrand, France (D.L.); and Division of Cardiology, University of Grenoble, Hôpital Nord, Grenoble, France (P.D.). * To whom correspondence should be addressed. E-mail: dakosta{at}aol.com.
Background--There is no published randomized study comparing amiodarone therapy and radiofrequency catheter ablation (RFA) after only 1 episode of symptomatic atrial flutter (AFL). The aim of the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) Trial of Atrial Flutter was 2-fold: (1) to prospectively compare first-line RFA (group I) versus cardioversion and amiodarone therapy (group II) after only 1 AFL episode; and (2) to determine the impact of both treatments on the long-term risk of subsequent atrial fibrillation (AF). Methods and Results--From October 2002 to February 2006, 104 patients (aged 78±5 years; 20 women) with AFL were included, with 52 patients in group I and 52 patients in group II. The cumulative risk of AFL or AF was interpreted with the use of Kaplan-Meier curves and compared by the log-rank test. Clinical presentation, echocardiographic data, and follow-up were as follows: age (78.5±5 versus 78±5 years), history of AF (27% versus 21.6%); structural heart disease (58% versus 65%), left ventricular ejection fraction (56±14% versus 54.5±14%), left atrial size (43±7 versus 43±6 mm), mean follow-up (13±6 versus 13±6 months; P=NS), recurrence of AFL (3.8% versus 29.5%; P<0.0001), and occurrence of significant AF beyond 10 minutes (25% versus 18%; P=0.3). Five complications (10%) were noted in group II (sick sinus syndrome in 2, hyperthyroidism in 1, and hypothyroidism in 2) and none in group I (0%) (P=0.03). Conclusions--RFA should be considered a first-line therapy even after the first episode of symptomatic AFL. There is a better long-term success rate, the same risk of subsequent AF, and fewer secondary effects.
Revised on July 14, 2006
Accepted on July 21, 2006
Results From the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) Trial on Atrial Flutter, a Multicentric Prospective Randomized Study Comparing Amiodarone and Radiofrequency Ablation After the First Episode of Symptomatic Atrial Flutter
Antoine Da Costa MD, PhD*,
Related Article:
Circulation 2006 114: 1669.
This article has been cited by other articles:
![]() |
C. Blomstrom-Lundqvist Drug treatment of supraventricular tachycardia Heart, November 1, 2009; 95(21): 1803 - 1807. [Full Text] [PDF] |
||||
![]() |
G. Barbato, V. Carinci, C. Tomasi, V. Frassineti, M. Margheri, and G. Di Pasquale Is electrocardiography a reliable tool for identifying patients with isthmus-dependent atrial flutter? Europace, August 1, 2009; 11(8): 1071 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Da Costa Catheter ablation procedures: role of nation-wide registries Europace, February 1, 2009; 11(2): 133 - 134. [Full Text] [PDF] |
||||
![]() |
J.#x.;n. Farré, H. J.J. Wellens, J.#x. M. Rubio, and J. Benezet CHAPTER 28 Supraventricular Tachycardias ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. C. Ng, G. T. Altemose, Q. Wu, K. Srivathsan, and L. R. P. Scott Typical Atrial Flutter as a Risk Factor for the Development of Atrial Fibrillation in Patients Without Otherwise Demonstrable Atrial Tachyarrhythmias Mayo Clin. Proc., June 1, 2008; 83(6): 646 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Scheinman and E. Keung The Year in Review of Clinical Cardiac Electrophysiology J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2075 - 2081. [Full Text] [PDF] |
||||
![]() |
P. Vassallo and R. G. Trohman Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications JAMA, September 19, 2007; 298(11): 1312 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
Catheter Ablation vs. Amiodarone for First Atrial Flutter in Elders Journal Watch Cardiology, November 14, 2006; 2006(1114): 4 - 4. [Full Text] |
||||
![]() |
D. G. Wyse Transvenous Radiofrequency Catheter Ablation for Atrial Flutter and Atrial Fibrillation: The End of the Beginning? Circulation, October 17, 2006; 114(16): 1670 - 1672. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |